- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01039480
Aspirin and Clopidogrel Resistance Study
February 8, 2012 updated by: University Hospital, Basel, Switzerland
Aspirin- and Clopidogrel-Resistance: Non-compliance and Other Contributing Factors
Resistance to antiplatelet drugs (aspirin, clopidogrel) is a recognized phenomenon with a prevalence from 17% to 35%.
Resistance as detected by in vitro tests such as Multiple Electrode Aggregometry (MEA) has been shown to predict clinical therapy failure.
Resistance can be caused by clinical, cellular and pharmacogenetic factors.
Non compliance is suspected to be an important contributing factor.
In this study, compliance will be assured with an electronical compliance monitoring system.
Factors to non response will be identified to find plausible explanations when in vitro platelet aggregation inhibition is insufficient despite assured compliance.
This study will help to disclose the relationship between compliance, biomarker and clinical outcome as well as to quantify the impact of non compliance to the resistance phenomenon as measured by MEA.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
82
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Solothurn
-
Olten, Solothurn, Switzerland, 4600
- Study Centre at Aarelab AG, Olten
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with a prescription for aspirin and/or clopidogrel seeing their general practitioner (GP) for any purpose
Description
Inclusion Criteria:
- Patients prescribed aspirin and/or clopidogrel for both including both cardiovascular and cerebrovascular indications seeing their general practitioner in or nearby Olten/SO for any medical purpose
- Patients with oral and written German language ability
Exclusion Criteria:
- Patients living in care homes
- Patients not preparing their drugs on their own (e.g. outpatient medical assistance through "spitex").
- Patients with acute cardiac symptoms
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
dual therapy (ASS/CLO)
patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
|
clopidogrel users (CLO)
patients with a prescription for clopidogrel
|
aspirin users (ASP)
patients with a prescription for aspirin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Platelet aggregation, initial and after one week under compliance monitoring.
Time Frame: 1 week
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Data on compliance (measured by electronic compliance monitoring, Morisky MMAS-8 and BMQ Score)
Time Frame: 1 week
|
1 week
|
Frequency of contributing factors to non-response in responders compared to non-responders (pharmacogenetics, clinical factors and drug-drug interactions)
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Kurt E Hersberger, PhD, Pharmaceutical Care Research Group, Departement of Pharmacy, University Basel
- Principal Investigator: Michel Romanens, MD, Kardiologische Praxis, Olten/SO
- Study Director: Dimitrios Tsakiris, MD, Hemostaseology Lab, University Hospital Basel
- Principal Investigator: Philipp N Walter, MSc, Pharmaceutical Care Research Group, Department of Pharmacy, University of Basel
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
December 23, 2009
First Submitted That Met QC Criteria
December 24, 2009
First Posted (Estimate)
December 25, 2009
Study Record Updates
Last Update Posted (Estimate)
February 9, 2012
Last Update Submitted That Met QC Criteria
February 8, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PCRG_003_PW
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Resistance
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingIncreased Drug Resistance | Resistance Bacterial | Drug Resistance, MicrobialBangladesh
-
Human Biome Institute S.A.RecruitingAntimicrobial Drug Resistance | Drug Resistance, BacterialPoland
-
University of AarhusDanish Research AgencyCompleted
-
National Institute of Mental Health (NIMH)Completed
-
Medstar Health Research InstituteUnknownIncreased Drug ResistanceUnited States
-
University Hospital, AkershusOslo University Hospital; Helse Stavanger HF; Sorlandet Hospital HF; Sykehuset... and other collaboratorsTerminatedAntibiotic Drug Resistance
-
Centre Hospitalier Universitaire de BesanconCompletedDrug Resistance, BacterialFrance
-
Tourcoing HospitalRecruitingDrug Resistance, Multiple, BacterialFrance
-
Christoph HatzUniversity of ZurichCompletedDrug Resistance, Multiple | Travel MedicineSwitzerland
-
Basilea PharmaceuticaCompletedDrug Resistance | Antimicrobial Agent | Cephalosporins